Project Grant R01AG092549
Award Date
5/15/25
Completion Date
2/28/30
Dollars Obligated
$561K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Indianapolis, IN 46202, USA
Similar Awards
This $3.38 million project grant from the National Institutes of Health's National Institute on Aging will fund research to repurpose FDA-approved agonists of the HCAR2 receptor as novel therapeutics for Alzheimer's disease. The grantee, Indiana University Iupui, will conduct preclinical studies using the 5XFAD mouse model of Alzheimer's disease to evaluate the therapeutic efficacy and pharmacological targets of the FDA-approved drugs niaspan and dimethyl fumarate in modulating microglial...
This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $2,181,250 in funding to the Seattle Institute For Biomedical And Clinical Research to develop small molecule inhibitors of the MSUT2 protein as a potential therapeutic approach for treating tauopathy disorders such as frontotemporal lobar degeneration, Alzheimer's disease, and related conditions. The project aims to optimize potent and brain-penetrant MSUT2 inhibitors and demonstrate...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $230,484 to The University of Iowa to investigate the reversal of tau protein pathology in serotonergic neurons as a potential therapeutic intervention for early Alzheimer's disease. The research aims to determine if directly restoring the activity of the phosphatase enzyme PP2A can reduce abnormally phosphorylated tau protein and mitigate the propagation of tau pathology in affected brain...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to identify and characterize novel tau protein proteoforms in blood that can differentiate healthy volunteers from those with Alzheimer's disease (AD) or progressive supranuclear palsy (PSP). The $2,186,322 award, effective August 15, 2024 through April 30, 2029, will be executed by the Trustees of Indiana University, doing business as Indiana University Indianapolis. The research seeks to...
The National Institute on Aging (NIA) awarded a $773,816 Project Grant (CFDA 93.866 - Aging Research) to the University of California, Irvine to conduct a comprehensive study on the molecular mechanisms underlying aberrant protein accumulation in Alzheimer's disease-related tauopathies. The project aims to generate cell-type-specific atlases of misprocessed RNAs and proteins in mouse models and human brain tissues to identify new pathways and protein interaction networks involved in...
The National Institute on Aging (NIA) awarded a $1,709,482 Project Grant (CFDA 93.866 - Aging Research) to the Seattle Institute for Biomedical and Clinical Research to investigate how the SUT-6/NIPP1 protein regulates pathological tau in Alzheimer's disease and other neurodegenerative "tauopathies". The 5-year grant, running from Aug 1, 2024 to Apr 30, 2029, aims to: 1) define the functions of SUT-6/NIPP1 important for suppressing tau toxicity; 2) determine downstream mediators of...
This federal Project Grant award of $1,118,700.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) to New York University School of Medicine will support research to elucidate the role of pathological tau protein in disrupting endosomal microautophagy (EMI), a critical protein degradation pathway affected in Alzheimer's disease. The research aims to determine which components of the EMI pathway are most vulnerable to tau pathology and whether restoring EMI function can...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to The Johns Hopkins University provides $146,922 to investigate physiological pathways modulating tau homeostasis, with potential implications for Alzheimer's disease and related dementias. The primary research objectives are to: Examine how the loss of the glycerophosphodiester phosphodiesterase 2 (GDE2) protein affects the onset and progression of neurodegeneration, tau modifications, and...
This $734,778 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports the development of human induced pluripotent stem cell (iPSC)-derived chimeric antigen receptor (CAR) macrophages to target tau-induced pathology and associated inflammation in Alzheimer's disease and related dementias. The project will evaluate novel CAR designs for targeting pathogenic tau protein, as well as leverage multiplex base editing in iPSCs to deactivate key inflammatory...
This federal Project Grant award of $431,750 from the National Institute on Aging's Aging Research program (CFDA 93.866) aims to develop an immunotherapy approach for treating tauopathies, a group of neurodegenerative disorders including Alzheimer's disease. The key product being developed is an adeno-associated virus (AAV) vector encoding a single-chain fragment variable (scFv) antibody that specifically targets and promotes the degradation of tau oligomers, which are considered a central...